Nippon Chemiphar’s Generics Business Continues To Recover

As Japanese Company Sees 2.4% Growth In Generics Segment

 
• By Akriti Seth
  
recovery
Nippon Chemiphar is on its road to recovery with single-digit growth in generics segment • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business